IN8bio (INAB) vs Senti Biosciences (SNTI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
IN8bio (INAB) has outperformed Senti Biosciences (SNTI) over the past year, losing 42.7% versus a loss of 81.9%. Over five years, INAB leads with a -99.2% price change compared with -99.7% for SNTI. IN8bio is the larger company by market cap ($13.3 million vs $9.9 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | INAB | SNTI |
|---|---|---|
| Share price | $1.35 | $0.3179 |
| Market cap | $13.31M | $9.90M |
| 1-day change | -2.17% | -1.18% |
| YTD return | -41.03% | -69.07% |
| 1-year return | -42.74% | -81.93% |
| 5-year return | -99.23% | -99.68% |
| EPS (TTM) | $-1.62 | $-1.72 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.73 | $2.88 |
| 52-week low | $0.88 | $0.29 |
| Distance from 52-week high | -50.55% | -88.96% |
| Analyst consensus | none | none |
| Avg. price target upside | +418.52% | +4146.62% |
| Average volume | 58.36K | 573.78K |
| Shares outstanding | 9.86M | 31.15M |
| Employees | 18 | 39 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- INAB has outperformed SNTI by 39.2 percentage points over the past year.
About IN8bio
INAB stock →IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with hematologic malignancies undergoing hematopoietic stem cell transplantation.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 18 employees
About Senti Biosciences
SNTI stock →Senti Biosciences Holdings, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The company's lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies in various oncology indications with unmet need.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 39 employees
INAB vs SNTI FAQ
Which is bigger, IN8bio or Senti Biosciences?
IN8bio (INAB) is larger, with a market capitalization of $13.31M compared with $9.90M for Senti Biosciences (SNTI).
Which stock has performed better over the past year, INAB or SNTI?
INAB returned -42.74% over the past 12 months, compared with -81.93% for SNTI (price return, excluding dividends). Past performance does not predict future results.
Are IN8bio and Senti Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.